Literature DB >> 33262083

Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States.

Matteo Santoni1, Francesco Piva2, Camillo Porta3, Sergio Bracarda4, Daniel Y Heng5, Marc R Matrana6, Enrique Grande7, Veronica Mollica8, Gaetano Aurilio9, Mimma Rizzo10, Matteo Giulietti2, Rodolfo Montironi11, Francesco Massari12.   

Abstract

INTRODUCTION: The incidence of kidney cancer is increasing; it could be counteracted with new ways to predict and detect it. We aimed to implement an artificial neural network in order to predict new cases of renal-cell carcinoma (RCC) in the population using population rate, obesity, smoking incidence, uncontrolled hypertension, and life expectancy data in the United States. PATIENTS AND METHODS: Statistics were collected on US population numbers, life expectancy, obesity, smoking, and hypertension. We used MATLAB R2018 (MathWorks) software to implement an artificial neural network. Data were repeatedly and randomly divided into training (70%) and validation (30%) subsets.
RESULTS: The number of new RCC cases will grow from 44,400 (2020) to 55,400 (2050), an increase of +24.7%. Our data show that preventing hypertension would have the greatest impact on reduction of the incidence, estimated at -775 and -575 cases per year in 2020 and in 2030, respectively. The prevention of obesity and smoking would have a more limited impact, estimated at -64 and -180 cases per year in 2020 and in 2030, respectively, for obesity, and -173 and -21 cases per year in 2020 and in 2030, respectively, for smoking.
CONCLUSIONS: Our predictions underline the need for accurate studies on RCC-related risk factors to reduce the incidence.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atezolizumab; Avelumab; Nivolumab; Pembrolizumab; Renal-cell carcinoma

Year:  2020        PMID: 33262083     DOI: 10.1016/j.clgc.2020.10.008

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  6 in total

1.  Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma.

Authors:  Veronica Mollica; Matteo Santoni; Marc R Matrana; Umberto Basso; Ugo De Giorgi; Alessandro Rizzo; Marco Maruzzo; Andrea Marchetti; Matteo Rosellini; Sara Bleve; Diana Maslov; Karine Tawagi; Ernest Philon; Zoe Blake; Francesco Massari
Journal:  Target Oncol       Date:  2021-12-11       Impact factor: 4.493

Review 2.  CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.

Authors:  Lan Li; Liping Zhong; Chao Tang; Lu Gan; Tong Mo; Jintong Na; Jian He; Yong Huang
Journal:  Clin Transl Oncol       Date:  2022-02-15       Impact factor: 3.340

Review 3.  Artificial intelligence-enabled decision support in nephrology.

Authors:  Tyler J Loftus; Benjamin Shickel; Tezcan Ozrazgat-Baslanti; Yuanfang Ren; Benjamin S Glicksberg; Jie Cao; Karandeep Singh; Lili Chan; Girish N Nadkarni; Azra Bihorac
Journal:  Nat Rev Nephrol       Date:  2022-04-22       Impact factor: 42.439

4.  Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

Authors:  Matteo Santoni; Francesco Massari; Sergio Bracarda; Giuseppe Procopio; Michele Milella; Ugo De Giorgi; Umberto Basso; Gaetano Aurilio; Lorena Incorvaia; Angelo Martignetti; Mimma Rizzo; Giacomo Cartenì; Enrique Grande; Marc R Matrana; Simon J Crabb; Nuno Vau; Giulia Sorgentoni; Alessia Cimadamore; Rodolfo Montironi; Nicola Battelli
Journal:  Diagnostics (Basel)       Date:  2021-01-18

Review 5.  The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors.

Authors:  Matteo Giulietti; Monia Cecati; Berina Sabanovic; Andrea Scirè; Alessia Cimadamore; Matteo Santoni; Rodolfo Montironi; Francesco Piva
Journal:  Diagnostics (Basel)       Date:  2021-01-30

Review 6.  The Urogenital System's Role in Diseases: A Synopsis.

Authors:  Maroun Bou Zerdan; Rita Moukarzel; Nour Sabiha Naji; Yara Bilen; Arun Nagarajan
Journal:  Cancers (Basel)       Date:  2022-07-08       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.